Briacell Therapeutics Corp宣布达成一项关键的生产安排。此举旨在确保其候选疗法在关键三期临床研究阶段拥有充足的生产能力,并为未来潜在的大规模商业化生产奠定坚实基础。
Briacell Therapeutics Corp宣布达成一项关键的生产安排。此举旨在确保其候选疗法在关键三期临床研究阶段拥有充足的生产能力,并为未来潜在的大规模商业化生产奠定坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.